Walleye Capital’s Strongbridge Biopharma plc. SBBP Stock Holding History

Walleye Capital’s Portfolio SBBP Stock Details SBBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-52,961	Closed	-$200K	–	1028
2020 Q2	$200K	Buy	+52,961	New	+$159K	0.04%	436

Other funds holding SBBP

Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Walleye Capital's SBBP Position: Q3 2020 in Review

Walleye Capital sold out of Strongbridge Biopharma plc. (SBBP) in Q3 2020, closing a stake of 52,961 shares — an estimated $200K sold.

Walleye Capital first reported a position in SBBP in Q2 2020 and held it in 1 quarter. The position peaked at $200K in Q2 2020. 77 funds tracked by Wall St. Rank hold SBBP as of Q3 2020.

Walleye Capital reported no remaining Strongbridge Biopharma plc. position as of Q3 2020 after selling out during the quarter.
Walleye Capital sold 52,961 Strongbridge Biopharma plc. shares in Q3 2020, an estimated $200K.
Walleye Capital first reported a position in Strongbridge Biopharma plc. in Q2 2020 and held it in 1 quarter.
Walleye Capital's Strongbridge Biopharma plc. position peaked at $200K in Q2 2020.
77 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q3 2020.

Based on Walleye Capital's 13F filing for Q3 2020, filed 16 Nov 2020.